FDA Asks for Feedback on Drug Compounding Forms
Published Date: 5/26/2026
Notice
Summary
The FDA wants your thoughts on how they collect info about making custom human drugs under special rules (Sections 503A and 503B). This affects pharmacies and drug makers who mix medicines just for patients. You’ve got until July 27, 2026, to share your comments—no cost changes yet, just a chance to help shape the paperwork process!
Analyzed Economic Effects
4 provisions identified: 0 benefits, 3 costs, 1 mixed.
Estimated Annual Paperwork Burden
FDA estimates the total annual reporting burden for human drug compounding at 9,500 hours and 17,461 responses. The agency provides a detailed breakdown (for example, 7,725 hours for 503A reporting and 880 hours for 503B recordkeeping of adverse events).
Adverse Event Reporting Deadlines and Records
Outsourcing facilities must submit serious and unexpected adverse event reports within 15 calendar days and submit follow-up reports within 15 calendar days of new information; they must retain adverse event records for 10 years and submit reports electronically via Form FDA 3500A, including current product labeling in the report.
503A Hospital/Health System Documentation Rules
Under FDA guidance for 503A compounding, a hospital or health system pharmacy relying on a prescriber's determination that a compounded drug is not essentially a copy must keep a statement from the prescriber that: (1) specifies the change from the commercially available product, (2) says the compounded drug will be administered only to patients for whom the change produces a significant difference, and (3) describes the intended patient population; those statements must be maintained on file.
New Cross‑Sector Stakeholder Group Burden
FDA added a cross-sector stakeholder group to this information collection: up to 30 stakeholders, about 9 meetings/activities each (270 responses total), adding an estimated 540 hours of respondent burden annually (about 2 hours per response).
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10371 — Advisory Committee; Drug Safety and Risk Management Advisory Committee; Renewal
The FDA is renewing its Drug Safety and Risk Management Advisory Committee for two more years, keeping it active until May 31, 2028. This committee helps the FDA make smart decisions about drug safety and risks, protecting everyone who uses medicines. No new costs or big changes, just a continued commitment to keeping drugs safe and sound.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
Previous / Next Documents
Previous: 2026-10371 — Advisory Committee; Drug Safety and Risk Management Advisory Committee; Renewal
The FDA is renewing its Drug Safety and Risk Management Advisory Committee for two more years, keeping it active until May 31, 2028. This committee helps the FDA make smart decisions about drug safety and risks, protecting everyone who uses medicines. No new costs or big changes, just a continued commitment to keeping drugs safe and sound.
Next: 2026-10374 — Louisiana Energy Services, LLC, dba Urenco USA; National Enrichment Facility; Revised Environmental Assessment and Finding of No Significant Impact
Louisiana Energy Services, also known as Urenco USA, got the green light to use a special container to ship uranium with a bit more enrichment than before—up to 10% U-235. The Nuclear Regulatory Commission checked the environmental impact again and confirmed it’s still safe with no big changes. This update kicks in starting May 26, 2026, helping Urenco USA keep their shipments smooth and secure.